JP6275239B2 - Ｈｍｗｐｅｇによる骨粗鬆症の管理 - Google Patents
Ｈｍｗｐｅｇによる骨粗鬆症の管理 Download PDFInfo
- Publication number
- JP6275239B2 JP6275239B2 JP2016502913A JP2016502913A JP6275239B2 JP 6275239 B2 JP6275239 B2 JP 6275239B2 JP 2016502913 A JP2016502913 A JP 2016502913A JP 2016502913 A JP2016502913 A JP 2016502913A JP 6275239 B2 JP6275239 B2 JP 6275239B2
- Authority
- JP
- Japan
- Prior art keywords
- bone
- polyethylene glycol
- peg
- hmw peg
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims description 321
- 239000002202 Polyethylene glycol Substances 0.000 claims description 313
- 241001465754 Metazoa Species 0.000 claims description 124
- 238000011282 treatment Methods 0.000 claims description 110
- 239000000203 mixture Substances 0.000 claims description 50
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 36
- 230000011164 ossification Effects 0.000 claims description 31
- 241000287828 Gallus gallus Species 0.000 claims description 29
- 235000013330 chicken meat Nutrition 0.000 claims description 24
- 230000012010 growth Effects 0.000 claims description 24
- 230000007423 decrease Effects 0.000 claims description 23
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 20
- 208000006386 Bone Resorption Diseases 0.000 claims description 18
- 208000020084 Bone disease Diseases 0.000 claims description 18
- 230000024279 bone resorption Effects 0.000 claims description 18
- 206010049088 Osteopenia Diseases 0.000 claims description 17
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
- 241000282887 Suidae Species 0.000 claims description 7
- 230000009245 menopause Effects 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 241000286209 Phasianidae Species 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 230000002262 irrigation Effects 0.000 claims description 3
- 238000003973 irrigation Methods 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 206010058359 Hypogonadism Diseases 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims description 2
- 230000008799 immune stress Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 description 147
- 241000699670 Mus sp. Species 0.000 description 99
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 50
- 206010065687 Bone loss Diseases 0.000 description 45
- 238000000034 method Methods 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 230000001054 cortical effect Effects 0.000 description 32
- 229910052500 inorganic mineral Inorganic materials 0.000 description 32
- 239000011707 mineral Substances 0.000 description 32
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 230000006872 improvement Effects 0.000 description 27
- 208000035475 disorder Diseases 0.000 description 26
- 102000004067 Osteocalcin Human genes 0.000 description 25
- 108090000573 Osteocalcin Proteins 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 25
- 241000271566 Aves Species 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 20
- 230000037180 bone health Effects 0.000 description 18
- 230000036541 health Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 210000000963 osteoblast Anatomy 0.000 description 12
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 210000002997 osteoclast Anatomy 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 230000001195 anabolic effect Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 244000144972 livestock Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940122361 Bisphosphonate Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000003982 Parathyroid hormone Human genes 0.000 description 6
- 108090000445 Parathyroid hormone Proteins 0.000 description 6
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 150000004663 bisphosphonates Chemical class 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 244000005709 gut microbiome Species 0.000 description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000010603 microCT Methods 0.000 description 6
- 229960001319 parathyroid hormone Drugs 0.000 description 6
- 239000000199 parathyroid hormone Substances 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 5
- 206010017076 Fracture Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003674 animal food additive Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- -1 Bisphosphonate compounds Chemical class 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000008108 Osteoprotegerin Human genes 0.000 description 3
- 108010035042 Osteoprotegerin Proteins 0.000 description 3
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 3
- 206010049514 Traumatic fracture Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 3
- 238000009806 oophorectomy Methods 0.000 description 3
- 230000002188 osteogenic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000000891 standard diet Nutrition 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 108010049264 Teriparatide Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical group S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical compound NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Chemical group 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Chemical group 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical group C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 101100493823 Mus musculus Best1 gene Proteins 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241001417495 Serranidae Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 102000014456 Trefoil Factor-3 Human genes 0.000 description 1
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108010059993 Vancomycin Chemical group 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940037127 actonel Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000037037 animal physiology Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229930182912 cyclosporin Chemical group 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 210000003275 diaphysis Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 230000027632 eggshell formation Effects 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229940053641 forteo Drugs 0.000 description 1
- 229940001490 fosamax Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 201000009863 inflammatory diarrhea Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229940060946 miralax Drugs 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940030786 moviprep Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000030432 tumor necrosis factor (ligand) superfamily member 11 production Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Chemical group O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798481P | 2013-03-15 | 2013-03-15 | |
| US61/798,481 | 2013-03-15 | ||
| PCT/US2014/028832 WO2014144425A1 (en) | 2013-03-15 | 2014-03-14 | Managing osteoporosis with hmw peg |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017024048A Division JP2017082009A (ja) | 2013-03-15 | 2017-02-13 | Ｈｍｗ ｐｅｇによる骨粗鬆症の管理 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513738A JP2016513738A (ja) | 2016-05-16 |
| JP2016513738A5 JP2016513738A5 (enExample) | 2017-03-16 |
| JP6275239B2 true JP6275239B2 (ja) | 2018-02-07 |
Family
ID=51537706
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502913A Active JP6275239B2 (ja) | 2013-03-15 | 2014-03-14 | Ｈｍｗｐｅｇによる骨粗鬆症の管理 |
| JP2017024048A Withdrawn JP2017082009A (ja) | 2013-03-15 | 2017-02-13 | Ｈｍｗ ｐｅｇによる骨粗鬆症の管理 |
| JP2018142353A Active JP6619849B2 (ja) | 2013-03-15 | 2018-07-30 | Ｈｍｗ ｐｅｇによる骨粗鬆症の管理 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017024048A Withdrawn JP2017082009A (ja) | 2013-03-15 | 2017-02-13 | Ｈｍｗ ｐｅｇによる骨粗鬆症の管理 |
| JP2018142353A Active JP6619849B2 (ja) | 2013-03-15 | 2018-07-30 | Ｈｍｗ ｐｅｇによる骨粗鬆症の管理 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10045949B2 (enExample) |
| EP (1) | EP2968159B1 (enExample) |
| JP (3) | JP6275239B2 (enExample) |
| AU (2) | AU2014229082C1 (enExample) |
| CY (1) | CY1122568T1 (enExample) |
| DK (1) | DK2968159T3 (enExample) |
| ES (1) | ES2744828T3 (enExample) |
| HU (1) | HUE045032T2 (enExample) |
| PL (1) | PL2968159T3 (enExample) |
| PT (1) | PT2968159T (enExample) |
| WO (1) | WO2014144425A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419823B (zh) * | 2020-04-30 | 2022-03-29 | 上海公谊药业有限公司 | 一种延胡索酸泰妙菌素肠溶微丸及其制备方法和用途 |
| NL1044084B1 (nl) | 2021-07-05 | 2023-01-11 | Evers Agro B V | Mestinjecteur |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10338646A (ja) | 1996-08-26 | 1998-12-22 | Takeda Chem Ind Ltd | 骨形成促進医薬組成物 |
| PT1567117E (pt) | 2002-11-26 | 2012-05-09 | Univ Chicago | Prevenção e tratamento de distúrbios epiteliais mediados por micróbios |
| WO2004105825A1 (ja) * | 2003-01-10 | 2004-12-09 | Taki Chemical Co., Ltd. | 骨形成用生体材料、該材料を含む注入用製剤、及び該材料を調製するためのキット、並びにこれらを用いる骨形成方法 |
| MXPA06012070A (es) * | 2004-04-20 | 2007-04-24 | Univ Chicago | Sistema de surtido terapeutico que comprende un compuesto de tipo peg de peso molecular alto. |
| US8840933B2 (en) * | 2006-05-03 | 2014-09-23 | Warsaw Orthopedic, Inc. | Method of treating neuronal injury by administering magnesium chloride and PEG |
| US9675696B2 (en) * | 2006-11-14 | 2017-06-13 | Warsaw Orthopedic, Inc. | Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain |
| US8153112B2 (en) * | 2007-08-03 | 2012-04-10 | Warsaw Orthopedic, Inc. | Compositions and methods for treating cavity conditions |
| WO2010111294A1 (en) | 2009-03-23 | 2010-09-30 | The University Of Chicago | Methods for preventing and treating radiation-induced epithelial disorders |
| EP2468265A3 (en) * | 2010-12-04 | 2013-01-02 | DEEF Pharmaceutical Industries Co. | Homogeneous preparations containing vitamin D |
-
2014
- 2014-03-14 HU HUE14764671A patent/HUE045032T2/hu unknown
- 2014-03-14 US US14/768,741 patent/US10045949B2/en active Active
- 2014-03-14 AU AU2014229082A patent/AU2014229082C1/en active Active
- 2014-03-14 JP JP2016502913A patent/JP6275239B2/ja active Active
- 2014-03-14 DK DK14764671.5T patent/DK2968159T3/da active
- 2014-03-14 ES ES14764671T patent/ES2744828T3/es active Active
- 2014-03-14 EP EP14764671.5A patent/EP2968159B1/en active Active
- 2014-03-14 WO PCT/US2014/028832 patent/WO2014144425A1/en not_active Ceased
- 2014-03-14 PL PL14764671T patent/PL2968159T3/pl unknown
- 2014-03-14 PT PT147646715T patent/PT2968159T/pt unknown
-
2017
- 2017-02-13 JP JP2017024048A patent/JP2017082009A/ja not_active Withdrawn
-
2018
- 2018-07-30 JP JP2018142353A patent/JP6619849B2/ja active Active
- 2018-08-10 US US16/101,145 patent/US20190015353A1/en not_active Abandoned
- 2018-10-19 AU AU2018250501A patent/AU2018250501B2/en active Active
-
2019
- 2019-09-05 CY CY20191100930T patent/CY1122568T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018250501A1 (en) | 2018-11-15 |
| DK2968159T3 (da) | 2019-08-12 |
| EP2968159B1 (en) | 2019-06-12 |
| US10045949B2 (en) | 2018-08-14 |
| JP2018162328A (ja) | 2018-10-18 |
| AU2014229082C1 (en) | 2019-01-17 |
| EP2968159A1 (en) | 2016-01-20 |
| ES2744828T3 (es) | 2020-02-26 |
| PL2968159T3 (pl) | 2019-11-29 |
| AU2014229082A1 (en) | 2015-11-05 |
| AU2018250501B2 (en) | 2020-06-25 |
| JP6619849B2 (ja) | 2019-12-11 |
| CY1122568T1 (el) | 2021-01-27 |
| PT2968159T (pt) | 2019-10-01 |
| JP2016513738A (ja) | 2016-05-16 |
| WO2014144425A1 (en) | 2014-09-18 |
| US20190015353A1 (en) | 2019-01-17 |
| US20160000730A1 (en) | 2016-01-07 |
| EP2968159A4 (en) | 2016-09-28 |
| JP2017082009A (ja) | 2017-05-18 |
| AU2014229082B2 (en) | 2018-07-19 |
| HUE045032T2 (hu) | 2019-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kempf et al. | Colistin use and colistin resistance in bacteria from animals | |
| Litten-Brown et al. | Porcine models for the metabolic syndrome, digestive and bone disorders: a general overview | |
| Tatara et al. | Prenatal programming of skeletal development in the offspring: effects of maternal treatment with β-hydroxy-β-methylbutyrate (HMB) on femur properties in pigs at slaughter age | |
| Suthongsa et al. | Effects of dietary levels of chito-oligosaccharide on ileal digestibility of nutrients, small intestinal morphology and crypt cell proliferation in weaned pigs | |
| Harris et al. | Inflammatory bowel disease causes reversible suppression of osteoblast and chondrocyte function in mice | |
| Tomaszewska et al. | Chronic dietary supplementation with kynurenic acid, a neuroactive metabolite of tryptophan, decreased body weight without negative influence on densitometry and mandibular bone biomechanical endurance in young rats | |
| MXPA04004904A (es) | Uso de glutamato, derivados o metabolitos de glutamato, analogos de glutamato o mezclas de los mismos para la preparacion de una composicion para el tratamiento de osteoporosis. | |
| JP6619849B2 (ja) | Ｈｍｗ ｐｅｇによる骨粗鬆症の管理 | |
| Wang et al. | Dietary zinc glycine supplementation improves tibia quality of meat ducks by modulating the intestinal barrier and bone resorption | |
| Tyagi | Mechanism of action of gut microbiota and probiotic Lactobacillus rhamnosus GG on skeletal remodeling in mice | |
| Barreiro et al. | Densitometric and biochemical values of broiler tibias at different ages | |
| Fuchs et al. | A comparison of the carcase characteristics of pigs immunized with a ‘gonadotrophin-releasing factor (GnRF)’vaccine against boar taint with physically castrated pigs | |
| Harvey et al. | Effect of daily lithium chloride administration on bone mass and strength in growing broiler chickens | |
| Tang et al. | Deletion of vitamin D receptor exacerbated temporomandibular joint pathological changes under abnormal mechanical stimulation | |
| Zeni et al. | Differences in bone turnover and skeletal response to thyroid hormone treatment between estrogen-depleted and repleted rats | |
| Yan | The effects of dietary probiotic inclusion on skeletal health of poultry and its possible mechanisms | |
| KR20190100187A (ko) | 다중 골연골종(mo)을 치료하는 방법 | |
| Somagond et al. | Effect of physical form of the therapeutic diet on the behaviour of crossbred calves experimentally infected with foot-and-mouth disease virus | |
| Tymczyna et al. | Interrelationships between morphometric, densitometric, and mechanical properties of mandible in 6-month-old male pigs | |
| Sumon et al. | Impacts of caponization on growth performance, certain phenotypic trait, and carcass composition in Sonali chicken: A randomized prospective study | |
| Dumas et al. | Effect of creep and post-weaning feeding composition on piglets’ intestinal health and post-weaning growth according to their creep feed consumption status | |
| JP7227962B2 (ja) | 筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物 | |
| Esmaeili | Effects of Probiotic Lactobacilli Administration during Pregnancy on the Bone of CD-1 Mouse Dams at Weaning | |
| Stacenko et al. | Usage of “Feed Back” as an ecologically safe and effective means for preventing rotoviral infection of piglets | |
| Hasan | Chondronecrosis with Osteomyelitis in broilers: Bacterial species involvement and influence of Probiotics and Synbiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170213 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171128 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171220 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180109 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6275239 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |